Nasus Pharma logo

Nasus Pharma(NYSEMKT) NSRX

Market Cap$37.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2025)-61%
5 YearN/A
1 Year-58%
1 Month-13%
$3.20
+0.63%
+0.02Today
Nasus Pharma last closing stock price
MetricPriceDate
Last closeUSD 3.182026-10-14
Nasus Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-15.76%USD 3.782026-10-07
1 month-12.88%USD 3.652026-09-14
3 month+3.58%USD 3.072026-07-16
Year to date-65.25%USD 9.152025-12-31
1 year-58.43%USD 7.652025-10-14
Since inception-61.45%USD 8.252025-08-13

Nasus Pharma Financials at a Glance

Market Cap

$37.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.93M

EPS (TTM)

-$0.33

P/E Ratio

-9.60

Dividend

$0.00

Beta (Volatility)

1.21 (Average)

Price

$3.20

Volume

6,242.532

Open

$3.22

Previous Close

$3.18

Daily Range

$3.05 - $3.22

52-Week Range

$1.98 - $9.50

Estimated Earnings Date

Jul 1, 2026

NSRX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nasus Pharma

Nasus Pharma Ltd. is a clinical-stage specialty pharmaceutical company focused on developing intranasal drugs for emergency medical conditions. The company aims to address acute medical situations and public health threats through innovative Powder-Based Intranasal (PBI) products.

Products and Services
  • NS002: Intranasal Epinephrine for severe allergic reactions
  • NS001: Intranasal Naloxone powder nasal spray for opioid overdose treatment
  • Research and development of additional intranasal therapies
Growth Outlook
  • Strong market demand for emergency medical treatments drives potential revenue growth
  • Expansion of product pipeline with innovative intranasal therapies planned
  • Increased awareness of opioid crisis enhances market opportunity for Naloxone products
Financial Highlights
  • Recent quarterly net income of -$5.94 million reflects ongoing R&D investments
  • Cash and short-term investments total $11.82 million, providing operational runway
  • Current ratio of 8.77 indicates strong liquidity position
Nasus Pharma Ltd. is positioned in the healthcare sector, specifically within the medical pharmaceuticals industry. The company has developed a unique approach to treating critical medical conditions through its intranasal drug delivery system. The focus on emergency medical situations, particularly in the context of the opioid crisis, presents significant growth potential. Recent financial data indicates that while the company is currently operating at a loss, it maintains a robust liquidity position with substantial cash reserves. This financial strength allows for continued investment in research and development, which is crucial for bringing innovative products to market. The current ratio suggests that the company is well-equipped to meet its short-term obligations, further enhancing its stability as it navigates the clinical development landscape. Overall, Nasus Pharma Ltd. represents an intriguing opportunity for investors interested in the pharmaceutical sector, particularly those focused on innovative solutions for urgent medical needs.
AI Generated • Sep 19, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

7

CEO

Dan Teleman, MBA

Website

www.nasuspharma.com

Headquarters

Tel Aviv, TA 6744317, IL

NSRX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-158.83%

Return on Capital

-169.92%

Return on Assets

-87.81%

Earnings Yield

-10.42%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$37.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.71M

Volume

6.24K

Avg. Volume

16.24K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$10.71M

EBITDA

-$7.18M

Operating Cash Flow

-$3.36M

Capital Expenditure

-$5.55K

Free Cash Flow

-$3.36M

Cash & ST Invst.

$11.82M

Total Debt

$103.00K

Nasus Pharma Performance Analysis

Nasus Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Nasus Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Nasus Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.06N/A
20232023-12-31USD -0.03-44.1%
20242024-12-31USD -0.0545.3%
20252025-12-31USD -0.19310.2%
Nasus Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31-80.0%
Q22026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$37.24MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$5.32M

N/A

Employees

7

N/A

Net Income

-$5.94M

-849.2%

EBITDA

-$5.95M

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$11.82M

+4061.3%

Total Debt

$103.00K

-94.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$49.00K

N/A

Short Term Debt

$54.00K

-97.0%

Return on Assets

-87.81%

N/A

Return on Invested Capital

-96.93%

N/A

Free Cash Flow

-$1.99M

-1552.2%

Operating Cash Flow

-$1.99M

-1551.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LITSLite Strategy, Inc.
$1.20+2.14%
CRVOCervoMed Inc.
$2.25-1.75%
ACETAdicet Bio, Inc.
$5.06+3.49%
GANXGain Therapeutics, Inc.
$1.33+0.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.62-0.33%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$102.35-7.41%
CRWVCoreWeave
$67.26+2.25%
INTCIntel
$93.87-4.33%

Questions About NSRX

What is the current price of Nasus Pharma?

Nasus Pharma is trading at $3.20 per share.

What is the 52-week range for Nasus Pharma?

Over the past 52 weeks, Nasus Pharma has traded between $1.98 and $9.50.

How much debt does Nasus Pharma have?

As of the most recent reporting period, Nasus Pharma reported total debt of $37.02K.

How much cash does Nasus Pharma have on hand?

Nasus Pharma reported $405.07K in cash and cash equivalents in its most recent financial results.

What is Nasus Pharma’s dividend yield?

Nasus Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services